{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"1.4","value":"1.3"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"3.7","value":"1.4"},{"groupId":"OG002","lowerLimit":"0.9","upperLimit":"1.8","value":"1.2"},{"groupId":"OG003","lowerLimit":"1.1","upperLimit":"1.8","value":"1.3"},{"groupId":"OG004","lowerLimit":"1.1","upperLimit":"2.8","value":"1.4"},{"groupId":"OG005","lowerLimit":"0.7","upperLimit":"1.3","value":"1.2"},{"groupId":"OG006","lowerLimit":"1.1","upperLimit":"10.1","value":"1.2"},{"groupId":"OG007","lowerLimit":"0.3","upperLimit":"1.1","value":"0.7"},{"groupId":"OG008","lowerLimit":"1.7","upperLimit":"9.3","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"3"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ewing sarcoma.","id":"OG000","title":"Cohort 1"},{"description":"Participants with non-rhabdomyosarcoma soft tissue sarcoma.","id":"OG001","title":"Cohort 5"},{"description":"Participants with osteosarcoma.","id":"OG002","title":"Cohort 6"},{"description":"Participants with rhabdomyosarcoma.","id":"OG003","title":"Cohort 7"},{"description":"Participants with wilms tumor.","id":"OG004","title":"Cohort 8"},{"description":"Participants with other tumor types with documented PD-L1 expression.","id":"OG005","title":"Cohort 9"},{"description":"Participants with other tumor types without documented PD-L1 expression.","id":"OG006","title":"Cohort 10"},{"description":"Participants with rhabdoid tumor.","id":"OG007","title":"Cohort 11"},{"description":"Participants with atypical teratoid rhabdoid tumor.","id":"OG008","title":"Cohort 12"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"PFS as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors","type":"SECONDARY","unitOfMeasure":"Months"}